{"id":10627,"date":"2023-06-20T07:00:00","date_gmt":"2023-06-20T05:00:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023\/"},"modified":"2023-06-20T07:00:00","modified_gmt":"2023-06-20T05:00:00","slug":"irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023\/","title":{"rendered":"IRLAB presenterar data fr\u00e5n Fas IIb-studien med mesdopetam i PD-LIDs p\u00e5 MDS Congress 2023"},"content":{"rendered":"

[mfn_before_post]<\/p>\n

\n

G\u00f6teborg, Sverige, 20 juni 2023 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att bolaget kommer att h\u00e5lla en posterpresentation p\u00e5 kongressen International Congress of Parkinson\u2019s Disease and Movement Disorders\u00ae, MDS Congress, i K\u00f6penhamn, Danmark fr\u00e5n 27-31 augusti 2023. Posterpresentationen \u201cResults from IRL790C005 – A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily On-Time without Troublesome Dyskinesia in Patients with Parkinson\u2019s Disease\u201d presenteras av Joakim Tedroff, Chief Medical Officer p\u00e5 IRLAB.<\/strong><\/p>\n<\/div>\n

\n

Posterpresentationen \u201cResults from IRL790C005 – A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily On-Time without Troublesome Dyskinesia in Patients with Parkinson\u2019s Disease\u201d,<\/em> f\u00f6rfattades av Angelo Antonini vid avdelningen f\u00f6r neurovetenskap, Padua Universitet; Susanna Waters, Clas Sonesson, Johanna Landstr\u00f6m, Nicholas Waters och Joakim Tedroff p\u00e5 Integrative Research Laboratories Sweden AB (IRLAB).<\/p>\n

Organisationen International Parkinson and Movement Disorder Society<\/em> (MDS) samlar tusentals av kliniker, forskare, praktikanter och branschsupportrar med intresse f\u00f6r aktuell forskning och tillv\u00e4gag\u00e5ngss\u00e4tt f\u00f6r diagnos och behandling av r\u00f6relsesjukdomar vid sin \u00e5rliga kongress kallad International Congress of Parkinson's Disease and Movement Disorders\u00ae. Syftet med MDS kongressen \u00e4r att dela id\u00e9er, uppmuntra intresse bland alla som \u00e4r involverade i v\u00e5rd och forskningen av r\u00f6relsesjukdomar, att delta i MDS:s aktiviteter och att fr\u00e4mja den relaterade kliniska och vetenskapliga disciplinen.<\/p>\n

Detaljer om posterpresentationen:<\/p>\n

Titel:\u00a0Results from IRL790C005 – A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily On-Time without Troublesome Dyskinesia in Patients with Parkinson\u2019s Disease
Posternummer:\u00a022
Kategori:\u00a0Parkinson\u2019s Disease: Clinical Trials
Presentationsdatum:\u00a0Monday, August 28
Presentationstid:\u00a013:00 – 15:00
Poster hall: Exhibition Hall<\/p>\n

Alla accepterade posterpresentationer kommer att publiceras online i en extra upplaga till Movement Disorders<\/em>, den officiella tidskriften f\u00f6r International Parkinson and Movement Disorders Society, och p\u00e5 den s\u00f6kbara MDS-posterwebbplatsen, mdsabstracts.org<\/a> den 27 augusti 2023, 08:00 CEST.<\/p>\n<\/div>\n

\n

F\u00f6r mer information:<\/strong><\/p>\n

\n

Gunnar Olsson, VD
Telefon: +46 70 576 14 02
E-mail:\u00a0gunnar.olsson@irlab.se<\/a><\/p>\n<\/div>\n

\n

Om IRLAB<\/strong><\/p>\n

\n

IRLAB uppt\u00e4cker och utvecklar en portf\u00f6lj av transformativa behandlingar f\u00f6r alla stadier av Parkinsons sjukdom. Bolaget har sitt ursprung i Nobelpristagaren Prof. Arvid Carlssons forskargrupp och uppt\u00e4ckten av ett samband mellan hj\u00e4rnans signalsubstanser och CNS-st\u00f6rningar. Mesdopetam (IRL790), under utveckling f\u00f6r behandling av levodopa-inducerade dyskinesier, \u00e4r bolagets mest avancerade program och licensierades till Ipsen \u00e5r 2021. En andra kandidat, pirepemat (IRL752), befinner sig f\u00f6r n\u00e4rvarande i Fas IIb, och utv\u00e4rderas f\u00f6r sin effekt p\u00e5 balans och fallfrekvens vid Parkinson. Dessutom utvecklar bolaget \u00e4ven de tre prekliniska programmen IRL942, IRL757 och IRL1117 mot Fas I-studier. Pipelinen drivs av IRLAB:s egenutvecklade systembiologibaserade forskningsplattform Integrative Screening Process (ISP). IRLAB har sitt huvudkontor i Sverige och \u00e4r noterat p\u00e5 Nasdaq Stockholm (IRLAB A). F\u00f6r mer information, bes\u00f6k www.irlab.se<\/a>.<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

IRLAB presenterar data fr\u00e5n Fas IIb-studien med mesdopetam i PD-LIDs p\u00e5 MDS Congress 2023<\/a><\/p>\n<\/div>\n

[mfn_after_post]<\/p>\n","protected":false},"excerpt":{"rendered":"

G\u00f6teborg, Sverige, 20 juni 2023 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att bolaget kommer att h\u00e5lla en posterpresentation p\u00e5 kongressen International Congress of Parkinson\u2019s Disease and Movement Disorders\u00ae, MDS Congress, i K\u00f6penhamn, Danmark fr\u00e5n 27-31 augusti 2023. Posterpresentationen \u201cResults from IRL790C005 – A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily On-Time without Troublesome Dyskinesia in Patients with Parkinson\u2019s Disease\u201d presenteras av Joakim Tedroff, Chief Medical Officer p\u00e5 IRLAB.<\/p>\n","protected":false},"template":"","class_list":["post-10627","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nIRLAB presenterar data fr\u00e5n Fas IIb-studien med mesdopetam i PD-LIDs p\u00e5 MDS Congress 2023 - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB presenterar data fr\u00e5n Fas IIb-studien med mesdopetam i PD-LIDs p\u00e5 MDS Congress 2023 - IRLAB\" \/>\n<meta property=\"og:description\" content=\"G\u00f6teborg, Sverige, 20 juni 2023 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att bolaget kommer att h\u00e5lla en posterpresentation p\u00e5 kongressen International Congress of Parkinson\u2019s Disease and Movement Disorders\u00ae, MDS Congress, i K\u00f6penhamn, Danmark fr\u00e5n 27-31 augusti 2023. Posterpresentationen \u201cResults from IRL790C005 - A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily On-Time without Troublesome Dyskinesia in Patients with Parkinson\u2019s Disease\u201d presenteras av Joakim Tedroff, Chief Medical Officer p\u00e5 IRLAB.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023\/\",\"url\":\"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023\/\",\"name\":\"IRLAB presenterar data fr\u00e5n Fas IIb-studien med mesdopetam i PD-LIDs p\u00e5 MDS Congress 2023 - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2023-06-20T05:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB presenterar data fr\u00e5n Fas IIb-studien med mesdopetam i PD-LIDs p\u00e5 MDS Congress 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB presenterar data fr\u00e5n Fas IIb-studien med mesdopetam i PD-LIDs p\u00e5 MDS Congress 2023 - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB presenterar data fr\u00e5n Fas IIb-studien med mesdopetam i PD-LIDs p\u00e5 MDS Congress 2023 - IRLAB","og_description":"G\u00f6teborg, Sverige, 20 juni 2023 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att bolaget kommer att h\u00e5lla en posterpresentation p\u00e5 kongressen International Congress of Parkinson\u2019s Disease and Movement Disorders\u00ae, MDS Congress, i K\u00f6penhamn, Danmark fr\u00e5n 27-31 augusti 2023. Posterpresentationen \u201cResults from IRL790C005 - A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily On-Time without Troublesome Dyskinesia in Patients with Parkinson\u2019s Disease\u201d presenteras av Joakim Tedroff, Chief Medical Officer p\u00e5 IRLAB.","og_url":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023\/","url":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023\/","name":"IRLAB presenterar data fr\u00e5n Fas IIb-studien med mesdopetam i PD-LIDs p\u00e5 MDS Congress 2023 - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2023-06-20T05:00:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/mfn_news\/irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/mfn_news\/irlab-presenterar-data-fran-fas-iib-studien-med-mesdopetam-i-pd-lids-pa-mds-congress-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB presenterar data fr\u00e5n Fas IIb-studien med mesdopetam i PD-LIDs p\u00e5 MDS Congress 2023"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/10627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=10627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}